[The content of this article has been produced by our advertising partner.]
Advertisement
The LEAD event brings together top liver disease experts across APAC, providing a vital platform for advancing liver disease diagnosis and management. By discussing the latest clinical evidence, emerging trends, innovative solutions, and health policy issues, the event addresses unmet medical needs and promotes end-to-end patient care in the region.
In collaboration with the Hong Kong Association for the Study of Liver Disease (HKASLD) and Hong Kong Liver Cancer and Gastrointestinal Cancer Foundation (HKLCF), LEAD APAC 2024 brought together 160 international experts from diverse disciplines in liver cancer, or hepatocellular carcinoma (HCC) to discuss the clinical use of comprehensive liver disease solutions to facilitate early detection and collaborative care.
Opening the event, Lance Little, Head of Region for Roche Diagnostics Asia Pacific, spoke to the challenges of HCC in the region.
“Patients with HCC are often diagnosed at a late stage, and this significantly reduces the treatment options and prognosis for them,” he remarked, adding that the five-year survival rate is just 18 per cent, compared to 91 per cent for cancers such as breast cancer.
Advertisement
“There’s a lot of work ahead, especially since the Asia Pacific region has the highest incidence of HCC globally, with rates in countries like China and Vietnam two to three times above the world average,” he said, adding that early detection and cross-disciplinary collaboration are both highly important.